PlexBio Co (6572) Fair Value & Analysis
Healthcare · TW · Market cap 859M TWD
Fair value as of: Jul 21, 2026
From 1 valuation models · updated 20 days ago
Share price −5.6% over the past month.
Below-average quality, and screening another 62% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (3.39 TWD). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (1.79 TWD to 3.39 TWD) leaves room in how you read the outcome.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 21, 2026.
How to read this chart
8‑month range 5.49 TWD – 13.00 TWD · fair‑value band 1.79 TWD – 3.39 TWD · the 7.19 TWD price screens above the 2.71 TWD fair value. As of Jul 21, 2026.
Analysis
PlexBio Co (6572) currently trades at 7.19 TWD, while our model-based Fair Value estimate is 2.71 TWD, implying the stock looks roughly 62.3% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, PlexBio Co generated revenue of 127M TWD at a net margin of -49.2%. Revenue declined 27.4% year over year. It earns a return on equity of -18.2%. The balance sheet holds a net cash position of 261M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 1.79 TWD (bear case) to 3.39 TWD (bull case); at 7.19 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 39% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -62%, 6572 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 6572 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular …
Full company description
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PlexBio Co reported revenue of 127M TWD in FY2025 versus 125M TWD in FY2021, a compound +0.4%/yr. Reported net income was −62.5M TWD in FY2025.
6572 screens 62% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare PlexBio Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PlexBio Co (6572) overvalued or undervalued?
What is the fair value of 6572?
What is the quality score of 6572?
What is the revenue of PlexBio Co (6572)?
What is the net profit margin of 6572?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PlexBio Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.